Furthermore, Gupta and Salunke (19) discussed molecular markers of glioma, underscoring the need to distinguish oligodendrogliomas based on MGMT promoter methylation status, which may offer insights into tumor behavior and response to therapy. This evidence concerns the gene MGMT and oligodendroglioma.